PhRMA appreciates the opportunity to offer recommendations to achieve our shared goal of modernizing coverage and payment policies to support patient access to new medical advances. Our comments address opportunities to advance the use of digital health tools and real-world evidence (RWE) as well as to promote interoperability and evolve coverage and payment policies for breakthrough therapies, including potentially curative therapies.